RCAG
FOLD

Rehmann Capital Advisory Group’s Amicus Therapeutics FOLD Stock Holding History

Rehmann Capital Advisory Group’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-50
Closed -$781 – 2151
2018
Q2 		$781 Buy
+50
New +$756 ﹤0.01% 2011

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Rehmann Capital Advisory Group's FOLD Position: Q3 2018 in Review

Rehmann Capital Advisory Group sold out of Amicus Therapeutics (FOLD) in Q3 2018, closing a stake of 50 shares — an estimated $781 sold.

Rehmann Capital Advisory Group first reported a position in FOLD in Q2 2018 and held it in 1 quarter. The position peaked at $781 in Q2 2018. 204 funds tracked by Wall St. Rank hold FOLD as of Q3 2018.

  • Rehmann Capital Advisory Group reported no remaining Amicus Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 50 Amicus Therapeutics shares in Q3 2018, an estimated $781.
  • Rehmann Capital Advisory Group first reported a position in Amicus Therapeutics in Q2 2018 and held it in 1 quarter.
  • Rehmann Capital Advisory Group's Amicus Therapeutics position peaked at $781 in Q2 2018.
  • 204 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2018.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2018, filed 20 Nov 2018.